← Eichor
Study identifier: NCT07724587 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Effectiveness and Safety of Combined Research on Uremic Sarcopenia

Condition: Sarcopenia  ·  Sponsor: Ningbo Medical Center Lihuili Hospital

PhaseNA
Planned participants76
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Objective: To investigate the clinical efficacy and safety of mindfulness meditation during dialysis combined with pre-dialysis progressive resistance training (PRT) for sarcopenia in patients undergoing maintenance hemodialysis (MHD). Methods: In the randomized controlled trial, 76 MHD patients with sarcopenia were divided into three groups: control group (CG), sports group (SG), and intervention group (IG). All groups received standard dialysis, health education, and dietary guidance. The SG received pre-dialysis PRT, while the IG added mindfulness meditation during dialysis. Efficacy and safety were evaluated at baseline and after 12 weeks. Ultrasound assessments of muscle mass were conducted at baseline, week 4, week 8, and week 12.

This description comes directly from the study's public registry record.

Talk to the study team

yongyao wu  ·  8615967857855  ·  wuyongyao.12345@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Yongyao WuNingbo, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07724587